GlassScriptPhysician profile
Sherry Kelly
NPI 1558535237
$2,145.94
in general payments reported to CMS, 2019-2025
22 companies · $378 in 2025
The $378 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $518 · 2022: $602 · 2023: $421 · 2024: $227 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,026.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $400.98 | 2021-2023 | Trintellix |
| Lundbeck LLC | $307.70 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $221.75 | 2021-2025 | Caplyta |
| Abbvie INC. | $209.56 | 2021-2025 | |
| Alkermes, INC. | $174.32 | 2021-2024 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $159.61 | 2022-2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $140.84 | 2021-2024 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $109.01 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $61.67 | 2025 | Hetlioz, Fanapt |
| Ironshore Pharmaceuticals INC. | $57.27 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $39.69 | 2025 | Uzedy |
| Corcept Therapeutics | $38.70 | 2023 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $34.75 | 2025 | Cobenfy |
| Amgen INC. | $33.95 | 2022 | |
| Supernus Pharmaceuticals, INC. | $31.49 | 2023 | Qelbree |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $28.03 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $23.14 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.56 | 2025 | |
| Daiichi Sankyo INC. | $16.72 | 2021 | |
| Neurocrine Biosciences, INC. | $16.00 | 2022 | |
| Astellas Pharma US INC | $14.21 | 2023 | Veozah |
| Corium, LLC | $8.99 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.